title: Predicting monoamine oxidase inhibitory activity through ligand-based models.
abstract: The evolution of bio- and cheminformatics associated with the development of specialized software and increasing computer power has produced a great interest in theoretical in silico methods applied in drug rational design. These techniques apply the concept that "similar molecules have similar biological properties" that has been exploited in Medicinal Chemistry for years to design new molecules with desirable pharmacological profiles. Ligand-based methods are not dependent on receptor structural data and take into account two and three-dimensional molecular properties to assess similarity of new compounds in regards to the set of molecules with the biological property under study. Depending on the complexity of the calculation, there are different types of ligand-based methods, such as QSAR (Quantitative Structure- Activity Relationship) with 2D and 3D descriptors, CoMFA (Comparative Molecular Field Analysis) or pharmacophoric approaches. This work provides a description of a series of ligand-based models applied in the prediction of the inhibitory activity of monoamine oxidase (MAO) enzymes. The controlled regulation of the enzymes' function through the use of MAO inhibitors is used as a treatment in many psychiatric and neurological disorders, such as depression, anxiety, Alzheimer's and Parkinson's disease. For this reason, multiple scaffolds, such as substituted coumarins, indolylmethylamine or pyridazine derivatives were synthesized and assayed toward MAO-A and MAO-B inhibition. Our intention is to focus on the description of ligand-based models to provide new insights in the relationship between the MAO inhibitory activity and the molecular structure of the different inhibitors, and further study enzyme selectivity and possible mechanisms of action.
authors.affiliation: Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela 15782, Spain. qosanti@yahoo.es
authors.forename: Santiago
authors.initials: S
authors.lastname: Vilar
authors.forename: Giulio
authors.initials: G
authors.lastname: Ferino
authors.forename: Elias
authors.initials: E
authors.lastname: Quezada
authors.forename: Lourdes
authors.initials: L
authors.lastname: Santana
authors.forename: Carol
authors.initials: C
authors.lastname: Friedman
mesh_terms: D006801:Humans; D008024:Ligands; D008956:Models, Chemical; D008958:Models, Molecular; D008995:Monoamine Oxidase / Q000378:metabolism*; D008996:Monoamine Oxidase Inhibitors / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D019636:Neurodegenerative Diseases / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism; D021281:Quantitative Structure-Activity Relationship
chemical_list: D008024:Ligands; D008996:Monoamine Oxidase Inhibitors; D008995:Monoamine Oxidase